Immutep doses first patient in TACTI-002 Phase II trial
8 March 2019 | Immutep has just announced that the first patient has been dosed in a new Phase II clinical trial (TACTI-002) which will evaluate the combination of their lead product candidate, eftilagimod alpha (“efti”), and KEYTRUDA®…
Immutep announces data from ongoing TACTI-mel Phase I clinical trial in unresectable or metastatic melanoma
8 March 2019 | This week at the World Immunotherapy Congress 2019 in San Diego USA, Immutep announced positive, more mature data from its ongoing TACTI-mel phase I clinical study of the company’s lead product candidate, eftilagimod alpha…
Mayne Pharma treatment for chronic breathlessness approved by TGA
20 February 2019 | Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that the Therapeutic Goods Administration (TGA) has approved KAPANOL® low dose sustained-release 10mg and 20mg morphine capsules for the treatment of chronic breathlessness in…
Nominations open for the Bionics Institute Award for Excellence in Medical Device Innovation
15 February 2019 | Nominations are now open for the Bionics Institute Award for Excellence in Medical Device Innovation. The 2019 Bionics Institute Award acknowledges an individual who, through their innovation, has made a significant impact on the…
Cartherics and panCELLa announce collaborative agreement to develop pluripotent cell lines for cell therapy
13 February 2019 Cartherics and panCELLa are pleased to announce their collaboration to research, develop and commercialise products for the treatment of cancer and other debilitating diseases using cell therapy. panCELLa will integrate their exclusive FailSafeTM technology into Cartherics’ proprietary…
Nucleus Network expands early phase trial capacity in Australia with acquisition of Q-Pharm
11 February 2019 Nucleus Network recently announced its acquisition of Q-Pharm, a 62-bed dedicated early-phase clinical trial facility based in the Herston health precinct in Brisbane. Q-Pharm was previously wholly owned by the QIMR Berghofer Medical Research Institute.…
4th Annual CEO Remuneration Report – Wexford Hayes
31 January 2019 This 4th annual CEO Remuneration report reviews the remuneration of the top 100 public companies listed on the Australian Securities Exchange for the Health Care & Biotechnology Sector. The report provides insight into remuneration in…
Sienna furthers its Global Expansion with Distributor for the Republic of Korea
22 January 2019 Highlights: Mirax Corporation appointed as exclusive distributor for Korea Important expansion of commercial opportunity in high-growth Asian IVD market Sienna Cancer Diagnostics Ltd a medical technology company developing and commercialising innovative cancer related tests, continues…
Super Charging The Immune System to Fight Cancer
22 January 2019 Innovative immunotherapies for cancer are a step closer to reality thanks to an agreement between Australia’s Cartherics Pty Ltd and Seoul-based ToolGen Inc. The agreement, signed in Melbourne on 21 January 2019, enables the companies…
Imagion Biosystems teams with Planet Innovation for MagSense™ instrument development
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, and Planet Innovation, a healthtech innovation and commercialization company, are pleased to announce that they have entered into a…
Design + Industry is now ISO 13485:2016 certified
BioMelbourne Network member Design + Industry (D+I) is proud to announce that they have achieved ISO 13485:2016 certification — the culmination of a four-year effort and recognition of their commitment to design and engineering excellence in the development…
2019 ARCS Annual Conference: call for session and program proposals extended
Interested parties from industry, research institutions, government and academia involved in development through to commercialisation of therapeutics (from bench to bedside) are invited to submit session proposals and program suggestions for the 2019 ARCS Annual Conference to be…
